Targeting systemic inflammation in atherosclerosis: Who will benefit?
نویسندگان
چکیده
منابع مشابه
Etanercept in juvenile idiopathic arthritis: Who will benefit?
Results 262 previously biologic-naive JIA-patients initiated etanercept; 71% female, 18% systemic-onset subtype. Median age at onset 6.9 (IQR 3.6-11.1) years, median followup 35.6 (IQR 17.4-53.6) months. In the long-term, the overall majority responded to etanercept and up to 40% reached inactive disease. Excellent response after 15 months (85 patients, 32%) was associated with low baseline dis...
متن کاملWho will benefit from tracheostomy ventilation in motor neuron disease?
The decision when to recommend tracheostomy ventilation in motor neuron disease (amyotrophic lateral sclerosis) has always been difficult. At one extreme is the view that when spontaneous ventilation or non-invasive ventilation is inadequate, a tracheostomy will save the patient’s life and lead to prolonged survival. This view has been more widely held in the USA than elsewhere. In the UK, a co...
متن کاملAdipoRon may be benefit for atherosclerosis prevention
Atherosclerosis has serious role in coronary arteries disease,so it is important to establish effective strategies for prevention or even treatment of atherosclerosis. Adiponectin, as one of the most abundant adipokines, has insulin sensitivity, anti-inflammatory and anti-atherogenic properties. Disturbed adiponectin actions through its receptor, (AdipoR1 and AdipoR2) may be involved in atheros...
متن کامل[Accelerated atherosclerosis and inflammation in systemic lupus erythematosus].
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that mainly affects young women, a group usually free of atherosclerosis. As treatment for SLE has improved during recent years and long term survival increased, it has become clear that patients with SLE have increased morbidity and mortality from atherosclerotic cardiovascular disease. Several imaging techniques s...
متن کاملAssociation between atherosclerosis and parenchymal lung involvement in systemic sclerosis
Background: Systemic sclerosis is an autoimmune disease affecting connective tissues, (including epidermal, subepidermal, microvasculature, etc.), leading to various extent of end-organ damage. The leading cause of mortality among these patients is lung involvement. The cardiovascular events happen more frequently in patients suffering systemic scleroderma, comparing to healthy population. This...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Preventive Cardiology
سال: 2018
ISSN: 2047-4873,2047-4881
DOI: 10.1177/2047487318774654